对甲状腺癌 (2013-2023) 向治疗的全球研究趋势的可视化分析
1Department of Thyroid Surgery, the Second Xiangya Hospital, Central South University, Changsha, P.R. China.
Medicine
|March 18, 2025
概括
本文献分析揭示了针对甲状腺癌 (TC) 向治疗的关键研究趋势. 它强调了领先的国家,机构和期刊推动TC治疗的进步,为未来的瘤学研究提供了见解.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 图书统计学 图书统计学
背景情况:
- 甲状腺癌 (TC) 往往呈现出高级阶段和侵略性的亚型,导致不良的临床结果.
- 向疗法为TC提供了有前途的新治疗途径.
- 对当前的研究趋势的全面了解对于推进TC治疗至关重要.
研究的目的:
- 分析和确定甲状腺癌 (TC) 向治疗的初级研究趋势.
- 通过检查出版模式,地理贡献,机构产出和有影响力的期刊,为研究人员提供事实基础.
- 了解TC向治疗研究的现状和趋势.
主要方法:
- 在2013年至2023年的出版物中,使用Web of Science核心集合 (WOSCC) 进行了文献计量分析.
- 使用VOSviewer,CiteSpace,Tableau和微软Excel进行数据分析.
- 搜索查询发现了763篇关于TC向治疗的出版物.
主要成果:
- 美国,中国和意大利是主要贡献者,美国在出版量方面处于领先地位.
- 研究活动在2021年达到顶峰,显示出波动性增长.
- 关键机构包括德克萨斯大学MD安德森癌症中心和比萨大学. 像"癌症"和"甲状腺"这样的期刊得到了高度引用.
- 全球研究成果和国际合作增加了.
结论:
- 本文献分析提供了针对性治疗的研究趋势的全面概述.
- 它确定了关键的开发过程和研究热点,指导未来的研究方向.
- 这些发现旨在刺激进一步的研究,促进TC瘤学的进步.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Synthesis and Regulation of Thyroid Hormones
4.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.1K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
315
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
315
Tumor Immunotherapy
454
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
454
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


